Abstract Search

ea0032p856 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Long-term safety of long-acting somatostatin analogues in combination with pegvisomant in 133 acromegalic patients, a retrospective single centre study with follow up for up to 8 years

Franck Sanne , van der Lely Aart-Jan , Koole Rita , de Rooij Felix , Neggers Sebastian

Introduction: Pegvisomant (PEGV) has an efficacy of >90% to control insulin-like growth factor-1. Main safety issues are elevated transaminases that seem to be related to Gilberts polymorphisms (GiPism) or gender and tumor-size increase (1).Aim: To assess safety in the largest single center cohort of acromegalics using PEGV.Methods: Results are expressed as median (interquartile-range).One-hundred a...

0 shares

Endocrine Abstracts

Long-term safety of long-acting somatostatin analogues in combination with pegvisomant in 133 acromegalic patients, a retrospective single centre study with follow up for up to 8 years

BiosciAbstracts